A study of enfortumab vedotin given in the bladder for treatment of patients with non-muscle invasive bladder cancer (NMIBC).
This research study is about a new treatment for a type of bladder cancer that has stayed in the lining of the bladder and hasn't grown into the muscle layer. This is called non-muscle invasive bladder cancer (NMIBC). The medicine, called enfortumab vedotin, is being given directly into the bladder. The aim is to see how safe it is and if it works for people with this condition. This is an early-stage study, meaning it's one of the first times this treatment is being tested in humans. Researchers want to understand more about how the body reacts to the medicine when it's given this way. It's for adults aged 18 and over, and anyone can take part, regardless of whether they are male or female.
Auf einen Blick
Worum geht es in dieser Studie?
This study is investigating a new way to treat a specific type of bladder cancer. This cancer is called "non-muscle invasive bladder cancer" (NMIBC), which means the cancer cells are only in the inner lining of the bladder and haven't spread deeper into the bladder muscle. This is good news, but it still needs careful treatment.
The new treatment being tested is a medicine called enfortumab vedotin. Instead of taking it as a pill or injection elsewhere in the body, this study is exploring giving the medicine directly into your bladder using a small tube. The idea behind this is to deliver the treatment right where the cancer is located, hoping it can be more effective and have fewer side effects on other parts of your body.
This is an early-stage study, sometimes called a "Phase I" study. This means the main goals are to find out if the treatment is safe when given directly into the bladder, and what dose might be best. We also want to learn if it shows any signs of working against the cancer. Studies like this are a really important step in developing new medicines and making sure they are as good and safe as possible for patients in the future.
Wichtige Erkenntnisse
- This study is for adults with non-muscle invasive bladder cancer.
- It tests a new medicine, enfortumab vedotin, given directly into the bladder.
- It's an early-stage study to check safety and potential effectiveness.
- Participation involves regular clinic visits for treatment and monitoring.
- Sie können jederzeit von der Studie zurücktreten.
Wer könnte berechtigt sein?
To join this study, you generally need to be an adult, aged 18 or older. The study is open to both men and women.
Crucially, you must have been diagnosed with "non-muscle invasive bladder cancer" (NMIBC). This means your bladder cancer has not spread into the muscle wall of your bladder.
More detailed checks will be done by the study doctors to make sure it's safe and right for you to take part. For example, they will look at your overall health.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Have you been diagnosed with bladder cancer?
- Has your bladder cancer *not* spread into the muscle wall (non-muscle invasive)?
- Are you willing to attend regular clinic appointments for the treatment?
Was beinhaltet die Teilnahme?
If you decide to take part, you would receive the study medication, enfortumab vedotin, which would be given directly into your bladder. This is typically done by inserting a thin tube (catheter) into your bladder. You would have regular appointments at the hospital or clinic so the study team can monitor your health closely, check for any side effects, and see how you are responding to the treatment.
These visits might involve blood tests, urine tests, and other examinations to keep track of your condition. The full duration of your participation, including how often you receive the medication and how long you are followed up, will be clearly explained by the study team. It's important to know the exact schedule of visits and procedures before you agree to join.
Potenzielle Risiken und Vorteile
Standorte (3)
- —UnbestätigtFrankreich
- —UnbestätigtSpanien
- —UnbestätigtDeutschland
Häufige Fragen
What is 'non-muscle invasive bladder cancer'?
It's a type of bladder cancer where the cancer cells are only in the inner lining of the bladder and haven't spread into the bladder muscle.
What is enfortumab vedotin?
It's the name of the new medicine being tested in this study for bladder cancer.
How is the medicine given in this study?
It's given directly into your bladder using a thin tube.
What is a 'Phase I' study?
It's an early-stage study, mainly focused on checking if a new treatment is safe and finding the right dose in people.
Kann ich die Studie verlassen, wenn ich meine Meinung ändere?
Yes, you can always choose to stop participating in the study at any time, and it won't affect your future medical care.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.